Want to see MLEC full AI Analyst Report?
Moolec Science (MLEC) AI Stock Analysis
Moolec Science
(NASDAQ:MLEC)
Moolec Science earns a low overall score primarily driven by acute solvency risks, extensive debt, and heavy cash burn. Although its exceptional top-line revenue expansion marks a notable operational milestone, extreme unprofitability and poor technical trends highlight a highly speculative investment with severe downside risk.
Moolec Science (MLEC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.02M
- Dividend Yield
- ―
- Average Volume (3M)
- 39.05K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 0.03
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 103
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Moolec Science Business Overview & Revenue Model
Company Description
Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and in...
How the Company Makes Money
null
Moolec Science Earnings Call Summary
The earnings call reflects a positive sentiment with significant achievements in revenue growth, regulatory approvals, and strategic partnerships. However, there are challenges with increased operating expenses and cash utilization.
Q4-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During Moolec Science's fourth quarter and full fiscal year 2024 conference call, the company shared key financial metrics and future guidance. The fiscal year 2024 saw a significant increase in normalized revenues, jumping from approximately $1 million in 2023 to $5.8 million in 2024, largely due to the consolidation of the soy product ingredient business. The cost of sales increased correspondingly, from close to $1 million in 2023 to $4.5 million in 2024, resulting in an annual gross margin that remains undisclosed. Expenses, including SG&A and R&D, rose by $3.1 million, reaching $9.3 million, driven by non-cash items and the soy ingredient business consolidation. Cash utilization in operating activities increased from $7.5 million in 2023 to $9.3 million in 2024, with a significant $4 million reduction in accounts payable. As of Q4 2024, the cash position stood at approximately $5.4 million, bolstered by the strategic purchase of 15,000 tons of HB4 soybean. Looking ahead, Moolec anticipates fiscal year 2025 to be pivotal, with the commercialization of new science-based ingredients like Glaso, supported by a three-year contract with a major CPG company, and efforts to enhance operational efficiencies and regulatory progress.
Moolec Science Financial Statement Overview
Summary
Despite explosive revenue growth and improved gross margins, the company faces severe financial distress characterized by deeply negative stockholders' equity, massive operating losses, and significant cash burn.
Income Statement
58NeutralBalance Sheet
12Very NegativeCash Flow
25Negative| Breakdown | TTM | Sep 2024 | Sep 2023 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.44M | 333.61M | 5.63M | 905.05K | 0 | 0 |
| Gross Profit | 25.74K | 114.01M | 472.58K | -143.31K | 0 | 0 |
| EBITDA | -5.79M | -69.01M | 14.14M | -51.74M | -3.65M | -13.80K |
| Net Income | -7.64M | -111.46M | -7.31M | -51.79M | -4.53M | -13.80K |
Balance Sheet | ||||||
| Total Assets | 32.56M | 204.71M | 34.79M | 24.05M | 5.69M | 138.59M |
| Cash, Cash Equivalents and Short-Term Investments | 3.61M | 9.02M | 5.39M | 2.83M | 1.08M | 337.60K |
| Total Debt | 22.08M | 246.88M | 14.68M | 2.65M | 125.00K | 125.00K |
| Total Liabilities | 26.87M | 287.58M | 27.97M | 13.95M | 4.09M | 4.51M |
| Stockholders Equity | 5.69M | -65.97M | 6.82M | 10.11M | 1.60M | 134.08M |
Cash Flow | ||||||
| Free Cash Flow | -8.98M | -30.10M | -9.49M | -7.69M | -1.89M | -8,802 |
| Operating Cash Flow | -8.86M | -24.45M | -9.33M | -7.51M | -1.89M | -8,802 |
| Investing Cash Flow | -99.44K | -35.99M | 134.87K | -2.34M | -138.00M | 0 |
| Financing Cash Flow | 11.45M | 13.07M | 11.71M | 11.28M | 139.05M | 14.49K |
Moolec Science Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLEC, the sentiment is Negative. The current price of 1.39 is below the 20-day moving average (MA) of 2.26, below the 50-day MA of 4.70, and below the 200-day MA of 7.25, indicating a bearish trend. The MACD of -0.99 indicates Negative momentum. The RSI at 20.74 is Positive, neither overbought nor oversold. The STOCH value of 17.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLEC.
Moolec Science Risk Analysis
Moolec Science disclosed 3 risk factors in its most recent earnings report. Moolec Science reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksMoolec Science Peers Comparison
Overall Rating
ENSC45Neutral- MLEC40Underperform
AIM40Underperform
CLDI38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ENSC | 45Neutral | $8.19M | -0.15 | -1532.33% | ― | -39.29% | 27.41% |
| MLEC | 40Underperform | $1.02M | -0.01 | 376.84% | ― | ― | ― |
| AIM | 40Underperform | $6.16M | -0.04 | 952.76% | ― | -21.49% | 84.62% |
| CLDI | 38Underperform | $2.53M | -0.01 | -372.86% | ― | ― | 53.95% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MLEC | Moolec Science Sa | 1.40 | -8.33 | -85.62% | |
| AIM | Aim Immunotech Inc. | 0.15 | -1.85 | -92.33% | |
| ENSC | Ensysce Biosciences, Inc. | 0.42 | -1.73 | -80.42% | |
| CLDI | Calidi Biotherapeutics, Inc. | 0.69 | -23.79 | -97.19% |
Moolec Science Corporate Events
Moolec Science Faces Cayman Winding Up Petition Over Disputed Legal Fees
On July 8, 2026, Moolec Science SA reported receiving a winding up petition filed in the Grand Court of the Cayman Islands by Linklaters LLP over an alleged USD 2.3 million in unpaid legal fees tied to services procured under the company’s form...
Moolec Science Regains Nasdaq Compliance but Faces Year-Long Monitoring
On June 1, 2026, Moolec Science SA received notice from a Nasdaq Hearings Panel that it has regained compliance with all previously cited Nasdaq Capital Market continued listing requirements, including financial reporting, minimum bid price, and mini...
Moolec Science Shareholders Approve 2025 Accounts and Board Slate at May 13 AGM
Moolec Science SA held its virtual Annual General Meeting of shareholders on May 13, 2026, with 71.24% of the 2,080,437 ordinary shares entitled to vote represented, establishing a valid quorum. Shareholders approved the consolidated financial statem...
Moolec Science Swings to Profit on Subsidiary Deconsolidation in Latest Interim Results
On May 13, 2026, Moolec Science SA filed a Form 6-K with the U.S. Securities and Exchange Commission for the month of May 2026, incorporating by reference unaudited interim condensed consolidated financial statements. The filing covers the company...
Moolec Science Regains Nasdaq Compliance After Strengthening Equity Base
On May 13, 2026, Moolec Science SA announced that it has regained compliance with all Nasdaq Capital Market continued listing requirements related to minimum stockholders’ equity within the remediation period granted by a Nasdaq Hearings Panel....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: May 28, 2026